Other languages Aquestive Therapeutics, Inc.

Equities

AQST

US03843E1047

Market Closed - Nasdaq Other stock markets 21:00:00 01/05/2024 BST			5-day change	1st Jan Change
3.365 ^USD	+0.15%		-21.38%	+66.58%

04-29	Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children	MT
04-29	Transcript : Aquestive Therapeutics, Inc. - Special Call

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children	04-29
Aquestive Therapeutics, Inc Receives U.S. FDA Approval and Market Access for Libervant? Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm? (epinephrine) Sublingual Film	04-29
Aquestive Therapeutics, Inc. to Present Crossover Study Data for Libervant Buccal Film At 76th Annual Meeting of the American Academy of Neurology	04-12
Aquestive Therapeutics Files $250 Million Mixed Shelf	04-03
Aquestive Therapeutics, Inc. Appoints Abigail Jenkins to Board of Directors, Effective April 1, 2024	04-01
Top Midday Decliners	03-20
Sector Update: Health Care Stocks Steady Premarket Wednesday	03-20
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply	03-20
Top Premarket Decliners	03-20
Aquestive Therapeutics Prices $75 Million Common Stock Offering; Shares Slump Premarket	03-20
Aquestive Therapeutics Proposes Public Stock Offering -- Shares Drop	03-19
Sector Update: Health Care Stocks Edge Higher Premarket Friday	03-15
Aquestive Therapeutics' Anaphylm Demonstrates Faster Maximum Concentration Reach in Phase 3 Trial	03-14
Aquestive Therapeutics, Inc. Releases Positive Topline Clinical Data from Its Phase 3 Pivotal Pharmacokinetic (PK) Clinical Study of Anaphylm (Epinephrine) Sublingual Film and Findings from the FDA Type C meeting	03-14
Aquestive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05
Aquestive Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-05
Aquestive Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	03-05
Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm (epinephrine) Sublingual Film	12-05
Aquestive Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-06
Aquestive Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2023	11-06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Aquestive Therapeutics, Inc.

Equities

AQST

US03843E1047

Other languages

Filters